Patents by Inventor Illana Gozes
Illana Gozes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8067369Abstract: This invention relates to the use of ADNF polypeptides in the treatment of laser-induced retinal damage and related conditions.Type: GrantFiled: April 20, 2006Date of Patent: November 29, 2011Assignee: Ramot at Tel-Aviv UniversityInventors: Illana Gozes, Michael Belkin
-
Patent number: 8017578Abstract: This invention provides an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. The invention also provides a pharmaceutical composition comprising an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. In particular, the pharmaceutical composition of the invention is orally active. The invention further provides methods for reducing neuronal cell death, methods for reducing oxidative stress, and methods for reducing a condition associated with fetal alcohol syndrome using the ADNF polypeptides and the pharmaceutical compositions of the invention.Type: GrantFiled: April 14, 2008Date of Patent: September 13, 2011Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, Ramot at Tel-Aviv University Ltd.Inventors: Douglas Brenneman, Illana Gozes, Catherine Y. Spong, Albert Pinhasov, Eliezer Giladi
-
Patent number: 7960334Abstract: This invention relates to the use of ADNF III polypeptides in the treatment of mental diseases or disorders, including schizophrenia. Embodiments of the invention provide methods for treating mental disorders, including schizophrenia, in a subject by administering a NAP, an 8-amino-acid peptide derived from Activity Dependent Neurotrophic Factor (ADNF III), in an amount sufficient to reduce or eliminate symptoms. The ADNF III polypeptides include polypeptides, analogs, subsequences, and D-amino acid versions (either wholly D-amino acid peptides or mixed D- and L-amino acid peptides), and combinations thereof which contain the active core sites and provide neuroprotective and anti-schizophrenic functions.Type: GrantFiled: March 11, 2004Date of Patent: June 14, 2011Assignee: Ramot at Tel-Aviv University Ltd.Inventors: Illana Gozes, Roy N. Alcalay, Inna Divinski, Eliezer Giladi
-
Patent number: 7863247Abstract: The invention relates to methods for reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol in utero with an ADNF polypeptide (e.g, ADNF I polypeptides, ADNF III polypeptides, or mixtures of ADNF I and ADNF III polypeptides). In one embodiment, the present invention relates to methods for reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol in utero with a mixture of ADNF I and ADNF III polypeptides. The present invention further relates to methods for reducing neuronal cell death by contacting neuronal cells with a mixture of ADNF I and ADNF III polypeptides. Still further, the present invention relates to a pharmaceutical composition comprising a mixture of ADNF I and ADNF III polypeptides.Type: GrantFiled: March 10, 2000Date of Patent: January 4, 2011Assignee: Ramot-University Authority for Applied Research and Development Ltd.Inventors: Douglas E. Brenneman, Catherine Y. Spong, Illana Gozes, Merav Bassan, Rachel Zamostiano
-
Publication number: 20100303785Abstract: The invention is based on the discovery of a novel neuroprotective peptide. In addition, the invention rests on the discovery that the NAP peptide enhances the association of tau and the brain-specific beta tubulin subunit. In addition, NAP modifies microtubule assembly and dynamics, in part, by affecting the tyrosination of microtubule proteins. The invention provides compositions and methods for treatment and prevention of neuronal disorders, including NAP-binding and tau-binding agents, tau peptide mimetics, NAP-like and NAP-like tau peptide mimetics.Type: ApplicationFiled: January 10, 2008Publication date: December 2, 2010Inventors: Illana Gozes, Maya Maor, Saar Oz, David Dangoor, Inna Divinski
-
Publication number: 20100216723Abstract: This invention relates to NAP-like and SAL-like peptide mimetics, polypeptides, or small molecules derived from them, and their use in the treatment of neuronal dysfunction, neurodegenerative disorders cognitive deficits, neuropsychiatric disorders, and autoimmune disease.Type: ApplicationFiled: February 18, 2010Publication date: August 26, 2010Applicants: Ramot at Tel-Aviv University Ltd., Allon Therapeutics Inc.Inventors: Illana Gozes, Alistair Stewart, Maya Maor, Sharon Furman-Assaf
-
Publication number: 20090170780Abstract: This invention relates to the use of ADNF polypeptides in the treatment of laser-induced retinal damage and related conditions.Type: ApplicationFiled: April 20, 2006Publication date: July 2, 2009Applicant: Ramot at Tel Aviv University Ltd.Inventors: Illana Gozes, Michael Belkin
-
Publication number: 20090137469Abstract: This invention relates to the use of ADNF polypeptides in the treatment of neurotoxicity induced by chemical agents or by disease processes. The ADNF polypeptides include ADNF I and ADNF III (also referred to as ADNP) polypeptides, analogs, subsequences such as NAP and SAL, and D-amino acid versions (either wholly D-amino acid peptides or mixed D- and L-amino acid peptides), and combinations thereof which contain their respective active core sites.Type: ApplicationFiled: October 3, 2008Publication date: May 28, 2009Applicants: Ramot at Tel-Aviv University, Allon Therapeutics, Inc.Inventors: Illana Gozes, James Miller
-
Publication number: 20090124543Abstract: The present invention relates generally to Activity Dependent Neurotrophic Factor III (ADNF III), also known as Activity Dependent Neuroprotective Protein (ADNP). More particularly, the present invention relates to nucleic acid sequences encoding ADNF III polypeptides; ADNF III polypeptides encoded by such nucleic acid sequences; antibodies to ADNF III polypeptides; and methods of using such ADNF III polypeptides for the treatment of neurological deficiencies and for the prevention of cell death associated with (1) gp120, the envelope protein from HIV; (2) N-methyl-D-aspartic acid (excito-toxicity); (3) tetrodotoxin (blockage of electrical activity); and (4) ?-amyloid peptide, a substance related to neuronal degeneration in Alzheimer's disease.Type: ApplicationFiled: August 13, 2007Publication date: May 14, 2009Applicants: The Govt. of the U.S.A., as represented by the Secretary of the Dept. of Health & Human Services, Ramot at Tel-Aviv University Ltd.Inventors: Illana Gozes, Douglas E. Brenneman, Merav Bassan, Rachel Zamostiano
-
Patent number: 7452867Abstract: This invention relates to the use of ADNF polypeptides in the treatment of neurotoxicity induced by chemical agents or by disease processes. The ADNF polypeptides include ADNF I and ADNF III (also referred to as ADNP) polypeptides, analogs, subsequences such as NAP and SAL, and D-amino acid versions (either wholly D-amino acid peptides or mixed D- and L-amino acid peptides), and combinations thereof which contain their respective active core sites.Type: GrantFiled: March 23, 2006Date of Patent: November 18, 2008Assignee: Ramot at Tel-Aviv University, Ltd.Inventors: Illana Gozes, James Miller
-
Patent number: 7427590Abstract: This invention relates to Activity Dependent Neurotrophic Factor I complex (ADNF I complex) and polypeptides of this complex, which produce their neurotrophic effects through multiple proteases intrinsic to the ADNF I complex. The invention also relates to pharmaceutical compositions comprising ADNF I complex polypeptides, as well as methods for reducing neuronal cell death in vitro and in vivo, methods for treating oxidative stress in a patient, methods for reducing a condition associated with fetal alcohol syndrome in a subject, and methods of enhancing learning and memory both pre- and post-natally, all of which methods use the ADNF I complex polypeptides of the invention.Type: GrantFiled: September 12, 2002Date of Patent: September 23, 2008Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, Ramot at Tel-Aviv University, Ltd.Inventors: Douglas E. Brenneman, Raquel Castellon, Catherine Y. Spong, Janet M. Hauser, Illana Gozes
-
Patent number: 7427598Abstract: The present invention provides methods for improving performance (e.g. learning and/or memory) using (ADNF) polypeptides, by treating the subject prenatally or postnatally with an Activity Dependent Neurotrophic Factor (ADNF) polypeptide in an amount sufficient to improve postnatal learning and/or memory of the subject.Type: GrantFiled: May 31, 2001Date of Patent: September 23, 2008Assignees: The United States of Americas as represented by the Secretary of the Department of Health and Human Services, Ramot at Tel-Aviv University, Ltd.Inventors: Catherine Y. Spong, Douglas Brenneman, Illana Gozes
-
Publication number: 20080194488Abstract: This invention provides an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. The invention also provides a pharmaceutical composition comprising an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. In particular, the pharmaceutical composition of the invention is orally active. The invention further provides methods for reducing neuronal cell death, methods for reducing oxidative stress, and methods for reducing a condition associated with fetal alcohol syndrome using the ADNF polypeptides and the pharmaceutical compositions of the invention.Type: ApplicationFiled: April 14, 2008Publication date: August 14, 2008Applicants: National Institute of Health, Ramot at Tel-Aviv University Ltd.Inventors: Illana Gozes, Albert Pinhasov, Eliezer Giladi, Douglas E. Brenneman, Catherine Y. Spong
-
Patent number: 7384908Abstract: This invention provides an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. The invention also provides a pharmaceutical composition comprising an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. In particular, the pharmaceutical composition of the invention is orally active. The invention further provides methods for reducing neuronal cell death, methods for reducing oxidative stress, and methods for reducing a condition associated with fetal alcohol syndrome using the ADNF polypeptides and the pharmaceutical compositions of the invention.Type: GrantFiled: August 17, 2000Date of Patent: June 10, 2008Assignee: National Institute of HealthInventors: Douglas E. Brenneman, Catherine Y. Spong, Illana Gozes, Albert Pinhasov, Eliezer Giladi
-
Patent number: 7264947Abstract: The present invention relates generally to Activity Dependent Neurotrophic Factor III (ADNF III), also known as Activity Dependent Neuroprotective Protein (ADNP). More particularly, the present invention relates to nucleic acid sequences encoding ADNF III polypeptides; ADNF III polypeptides encoded by such nucleic acid sequences; antibodies to ADNF III polypeptides; and methods of using such ADNF III polypeptides for the treatment of neurological deficiencies and for the prevention of cell death associated with (1) gp120, the envelope protein from HIV; (2) N-methyl-D-aspartic acid (excito-toxicity); (3) tetrodotoxin (blockage of electrical activity); and (4) ?-amyloid peptide, a substance related to neuronal degeneration in Alzheimer's disease.Type: GrantFiled: July 17, 2003Date of Patent: September 4, 2007Assignee: United States of America, as represented by the Secretary of the Department of Health and Human ServicesInventors: Illana Gozes, Douglas E. Brenneman, Merav Bassan, Rachel Zamostiano
-
Publication number: 20070054847Abstract: This invention relates to the use of ADNF polypeptides in the treatment of anxiety and/or depression. The present invention also relates to drug discovery assays using the ADNF polypeptide mechanism of action and target interaction, as well as the manufacture of medicaments, methods of application and formulation therefor. Embodiments of the invention provide methods for preventing and/or treating anxiety and depression disorders in a subject by administering a NAP, an 8-amino-acid peptide derived from Activity Dependent Neurotrophic Factor (ADNF III), in an amount sufficient to improve postnatal performance. The ADNF polypeptides include ADNF I and ADNF III (also referred to as ADNP) polypeptides, analogs, subsequences, and D-amino acid versions (either wholly D-amino acid peptides or mixed D- and L-amino acid peptides), and combinations thereof which contain their respective active core sites and provide neuroprotective and anti-anxiety functions.Type: ApplicationFiled: March 11, 2004Publication date: March 8, 2007Applicant: RAMOT at Tel Aviv University Ltd.Inventors: Illana Gozes, Roy Alcalay, Inna Divinski, Eliezer Giladi
-
Publication number: 20060247168Abstract: This invention relates to the use of ADNF polypeptides in the treatment of neurotoxicity induced by chemical agents or by disease processes. The ADNF polypeptides include ADNF I and ADNF III (also referred to as ADNP) polypeptides, analogs, subsequences such as NAP and SAL, and D-amino acid versions (either wholly D-amino acid peptides or mixed D- and L-amino acid peptides), and combinations thereof which contain their respective active core sites.Type: ApplicationFiled: March 23, 2006Publication date: November 2, 2006Applicants: Ramot at Tel-Aviv University Ltd., Allon Therapeutics, Inc.Inventors: Illana Gozes, James Miller
-
Patent number: 6933277Abstract: This invention relates to a method for reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol in utero with an ADNF polypeptide. In particular, the present invention relates to a method of reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol in utero with a combination of ADNF I and ADNF III polypeptides. The present invention further relates to a method for reducing neuronal cell death by contacting neuronal cells with a combination of ADNF I and ADNF III polypeptides. Still further, the present invention relates to a pharmaceutical composition comprising a combination of ADNF I and ADNF III polypeptides.Type: GrantFiled: March 12, 1999Date of Patent: August 23, 2005Assignees: The United States of America as represented by the Department of Health and Human Services, Ramot University Authority for Applied Research and Industrial Development, Ltd.Inventors: Douglas E. Brenneman, Catherine Y. Spong, Illana Gozes, Merav Bassan, Rachel Zamostiano
-
Publication number: 20050075284Abstract: The present invention relates to pharmaceutical compositions for the treatment of female sexual dysfunction, for vaginal relaxation and/or for modulation of sperm motility. The composition comprises as active ingredient (i) a peptide analogue or conjugate of vasoactive intestinal peptide (VIP) as defined in the specification and is preferably formulated for topical application in the vaginal, vulvar and/or clitorial area. The invention also relates to the use of the VIP peptide analogue or conjugate for the preparation of a pharmaceutical composition for the treatment of female sexual dysfunction, for vaginal relaxation and/or for modulation of sperm motility. Yet further, the invention provides a method of treatment of female sexual dysfunctions and/or vaginal relaxation by the use of said peptide analogue and/or conjugate.Type: ApplicationFiled: May 22, 2001Publication date: April 7, 2005Inventors: Illana Gozes, Matityahu Fridkin
-
Publication number: 20040235747Abstract: The present invention provides methods for preventing and/or treating autoimmune diseases, including multiple sclerosis, in a subject using ADNF polypeptides, by treating the subject with an Activity Dependent Neurotrophic Factor (ADNF) polypeptide.Type: ApplicationFiled: December 29, 2003Publication date: November 25, 2004Applicants: Ramot At Tel-Aviv University Ltd., The Govt. of the USA as represented by the Secretary of the Dept. of Health & Human ServicesInventors: Illana Gozes, Daniel Offen, Eliezer Giladi, Eldad Melamed, Douglas E. Brenneman